BD Acquires GenCell Biosystems
Becton, Dickinson and Company (BD) has announced its acquisition of GenCell Biosystems.
12 October 2014BD is an internationally renowned medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents.
BD is an internationally renowned medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The company is committed to helping all people live healthy lives.
BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.
BD Diagnostic Systems Molecular has a proven track record in fully automated molecular testing, with assays for Chlamydia trachomatis and Neisseria gonorrhoeae testing on its Viper XTR system.
Since 2011, BD’s new microfluidic platform, the BD MAX™ system for molecular testing, enables laboratories to run both user-developed and IVD assays and further enhances the diagnostics lab’s testing services to its clinical partners and healthcare institutes.
BD MAX™ is the first fully-automated bench top molecular system capable of simultaneously running pre-defined CE-IVD and user-defined customized assays and multiple specimen types with remarkable ease of use. Its versatility, the ability to customize the assay menu and the point of care characteristics make the system a highly desirable platform for the diagnostic lab.
The BD MAX™ platform is an open system that enables laboratories to program and automate user-defined thermocycling and PCR-analysis protocols. Laboratories can use user-defined protocols or other commercial assays in addition to those developed by the company.
All the reagents necessary for cell lysis, nucleic acid extraction, amplification and detection are contained in unitized reagent strips: pipette tips, lytic enzymes, extraction reagents, magnetic beads, wash buffers, master mix, probes, primers and internal control.
Only BD MAX™ allows you to gain access to assays developed by BD and to a wide range of assays developed by BD partners. Explore how versatility meets simplicity with BD MAX™.
All BD MAX™ IVD assays follow the same easy workflow consisting of:
There are a number of partner and BD-developed assays that are currently available for BD MAX™ system.
BD MAX™ MRSA assay to rapidly and accurately identify methicillin-resistant Staphylococcus aureus (MRSA) carriage in patients, enabling rapid and appropriate infection control measures for patient and bed management.
BD MAX™ Cdiff assay to rapidly and accurately identify patients with Clostridium difficile infection (CDI) enabling timely and appropriate treatment and infection control measures, and improved patient outcomes.
Diagenode Respiratory Influenza A/B assay (Europe only) to rapidly and accurately indentify human influenza A/B (HI.A/B) in patients, enabling timely and appropriate treatment. Manufactured by BD partner Diagenode.
There are currently more than 15 assays in development for the BD MAX™ system, all of which have target release dates in 2013.
Assays in development by BD include:
Assays being developed by BD partners include:
To learn more about BD’s range of products, or to make an enquiry, please contact us using the details below.
Becton, Dickinson and Company (BD) has announced its acquisition of GenCell Biosystems.
12 October 2014BD Medical has announced the nationwide retail pharmacy launch of BD AutoShield™ Duo at the annual meeting for the American Association of Diabetes Educators in Orlando, Florida.
5 August 2014BD Diagnostics has announced the availability of the Total Nucleic Acid (TNA) suite of reagents for the BD MAX System.
3 August 2014BD Diagnostics has announced it achieved CE/IVD Marking for the BD ProbeTec™ chlamydia trachomatis (CT), Qx Amplified DNA Assay and the BD ProbeTec Neisseria gonorrhoeae (GC) Qx Amplified DNA Assay on the BD Viper™ LT System.
27 July 2014BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the availability of the CE-marked BD MAX™ StaphSR assay with eXTended Detection Technology in Europe for use on the fully-automated BD MAX System.
2 September 2013BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), and Diagenode, an international biotech company based in Belgium, have announced the European-only launch of the Diagenode Bordetella pertussis/parapertussis real-time polymerase chain reaction (PCR) kit for use on the BD MAX™ System.
27 June 2013BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), and Diagenode SA, an international biotech company based in Belgium, announced today the European-only launch of the Diagenode Respiratory FLU A/B primers and probes kit for use on the BD MAX™ System.
14 November 2012Omicron, supply chains, and pandemic recovery are several themes likely to trend in the hospital sector this year.
Thank you for submitting the form. Your enquiry will be submitted to the company.
Thank you for subscribing to Hospital Management